Marizyme, Inc. (MRZM)

OTCMKTS · Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
At close: Oct 2, 2025
-100.00%
Market Cap 132.00
Revenue (ttm) 183.42K
Net Income (ttm) -14.95M
Shares Out 131.79M
EPS (ttm) -0.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 20,000
Average Volume 22,337
Open 0.0000
Previous Close 0.0000
Day's Range 0.0000 - 0.0000
52-Week Range 0.0000 - 0.1195
Beta 1.04
RSI 41.82
Earnings Date May 14, 2026

About Marizyme

Marizyme, Inc., a multi-technology life science company, engages in the research, manufacture, and commercialization of medical devices, diagnostics, and products to address clinical needs in the United States, Europe, and Asia. The company operates as a medical technology company that delivers solutions for coronary artery bypass graft surgery. Its product portfolio includes DuraGraft, a biocompatible intraoperative vascular graft storage and flushing solution; and Krillase, an enzyme that acts to break protein bonds and has applications in wo... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 13
Stock Exchange OTCMKTS
Ticker Symbol MRZM
Full Company Profile

Financial Performance

In 2023, Marizyme's revenue was $645,810, an increase of 176.60% compared to the previous year's $233,485. Losses were -$65.35 million, 71.2% more than in 2022.

Financial Statements

News

There is no news available yet.